Quantcast

Latest Enfuvirtide Stories

2011-02-07 15:32:35

Using mathematical concepts, Princeton researchers have developed a method of discovering new drugs for a range of diseases by calculating which physical properties of biological molecules may predict their effectiveness as medicines. The technique already has identified several potential new drugs that were shown to be effective for fighting strains of HIV by researchers at Johns Hopkins University. "The power of this is that it's a general method," said Princeton chemical and biological...

2011-01-03 07:45:00

TITUSVILLE, N.J., Jan. 3, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents. The recommended oral dose of INTELENCE tablets is 200 mg (one 200 mg...

2009-11-30 16:18:05

Publishing in PLoS Pathogens, researchers at from the Kimmel Cancer Center at Jefferson have found a novel mechanism by which drugs block HIV-1 from entering host cells. Cellular invasion by HIV-1 requires the concerted action of two proteins on the viral surface: gp120 and gp41. The function of gp41 is to get the viral contents into the interior of the host cells. This requires the association of two distinct regions of gp41 called N-HR and C-HR. Anti-HIV-1 agents known as fusion inhibitors...

2009-11-25 14:05:00

BRIDGEWATER, N.J., Nov. 25 /PRNewswire/ -- The FDA granted traditional approval for INTELENCE® (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). INTELENCE is the only NNRTI specifically indicated for use in treatment-experienced adults who are experiencing virologic failure with HIV-1 strains resistant to an NNRTI and other antiretroviral (ARV) agents. The traditional approval is based on 48-week data from two Phase 3 studies known as DUET-1...

2009-11-17 08:32:00

SEOUL, South Korea, Nov. 17 /PRNewswire/ -- Arigene Co., Ltd., a Korean corporation traded on the Korean Securities Dealers Association Quotation System ("Arigene") (KOSDAQ: 067850), today announced that it has entered into an amendment to its previously announced merger agreement dated October 2, 2009 with Trimeris, Inc. ("Trimeris") (Nasdaq: TRMS). The amendment provides for an extension of the expiration date of the tender offer being conducted by Arigene for Trimeris' outstanding...

2009-08-20 07:30:00

NAPLES, Fla., Aug. 20 /PRNewswire/ -- The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains....

2009-07-20 07:30:00

BRIDGEWATER, N.J., July 20 /PRNewswire/ -- Ninety-six week pooled results from two Phase 3 studies (DUET-1 and DUET-2) showed that significantly more treatment-experienced HIV-1-infected adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resistance had an undetectable viral load (<50 HIV-1 RNA copies/mL) while taking INTELENCE(TM) (etravirine) tablets plus background regimen (BR) compared with placebo plus BR. These findings were presented...

2009-02-05 07:45:00

BRIDGEWATER, N.J., Feb. 5 /PRNewswire/ -- Tibotec, Inc. today announced it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking traditional approval for INTELENCE(TM) (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). The application for traditional approval includes 48-week data from two Phase 3 studies known as DUET-1 and DUET-2. INTELENCE is currently marketed in the U.S. by Tibotec Therapeutics, a division of Centocor Ortho...

2008-10-23 06:00:27

Although once praised for its efficacy even in highly treatment-experienced patients, Fuzeon's high cost and cumbersome mode of administration have restricted its overall growth. Driven by the launch of three new orally available and relatively inexpensive drugs, global sales of Trimeris' HIV drug have now dropped by 38% in the third quarter of 2008. Trimeris announced worldwide net sales of its HIV entry inhibitor Fuzeon for the third quarter of 2008 were $45.5 million, down 38% from $73.9...

2008-10-22 09:00:10

BRIDGEWATER, N.J., Oct. 22 /PRNewswire/ -- The FDA has granted PREZISTA (darunavir) tablets, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults (those who have never taken HIV medication before). The FDA also granted traditional (full) approval to PREZISTA as twice-daily for use in treatment-experienced adult patients. PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related